Antitumor activity of sorafenib in FLT3-driven leukemic cells.
about
Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.Novel small molecule Raf kinase inhibitors for targeted cancer therapeuticsFLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML.Phosphoproteome Analysis Reveals Differential Mode of Action of Sorafenib in Wildtype and Mutated FLT3 Acute Myeloid Leukemia (AML) CellsFLT3-ITD knockin impairs hematopoietic stem cell quiescence/homeostasis, leading to myeloproliferative neoplasmPhase I study of sorafenib in patients with refractory or relapsed acute leukemiasDownregulation of signal transducer and activator of transcription 3 by sorafenib: a novel mechanism for hepatocellular carcinoma therapy.The Future of Targeting FLT3 Activation in AML.Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens.Treatment of FLT3-ITD acute myeloid leukemia.FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivoFLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia.Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia.The multitargeted receptor tyrosine kinase inhibitor linifanib (ABT-869) induces apoptosis through an Akt and glycogen synthase kinase 3β-dependent pathway.Remaining challenges in childhood cancer and newer targeted therapeutics.Computer aided drug discovery of highly ligand efficient, low molecular weight imidazopyridine analogs as FLT3 inhibitors.Homology modeling of DFG-in FMS-like tyrosine kinase 3 (FLT3) and structure-based virtual screening for inhibitor identification.BPR1J-097, a novel FLT3 kinase inhibitor, exerts potent inhibitory activity against AMLEmerging pharmacotherapies for adult patients with acute lymphoblastic leukemia.Targeted Therapy of FLT3 in Treatment of AML-Current Status and Future Directions.Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent processSKLB-677, an FLT3 and Wnt/β-catenin signaling inhibitor, displays potent activity in models of FLT3-driven AML.Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia.Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML.Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody.Nilotinib induces autophagy in hepatocellular carcinoma through AMPK activation.Synergistic cytotoxicity of sorafenib with busulfan and nucleoside analogs in human FMS-like tyrosine kinase 3 internal tandem duplications-positive acute myeloid leukemia cellsInitial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing programPotential role of sorafenib in the treatment of acute myeloid leukemia.AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)ATM/G6PD-driven redox metabolism promotes FLT3 inhibitor resistance in acute myeloid leukemia.Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutantsFLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML.Investigational drugs targeting FLT3 for leukemia.Elevated expression of eukaryotic translation initiation factor 3H is associated with proliferation, invasion and tumorigenicity in human hepatocellular carcinoma.TTT-3002 is a novel FLT3 tyrosine kinase inhibitor with activity against FLT3-associated leukemias in vitro and in vivo.Exploiting cellular pathways to develop new treatment strategies for AML.FLT3 inhibitors: a story of the old and the new.FMS-like tyrosine kinase 3 inhibitors: a patent review.Sorafenib for the management of advanced renal cell carcinoma.
P2860
Q27851423-CECCE48B-00B5-4472-9A76-7A34C478960AQ28265862-2A96CEB0-CA01-4191-9975-AFF113031AA6Q33680292-433FF1C3-B517-4CAA-941F-82FCC8A733D7Q33882022-EB1C061D-4B9E-4205-83B3-60637EDB5641Q34408941-FEED54A6-53CD-4B97-A42E-CBEDBB36DBD0Q34451540-304C43A7-2AB3-43A1-916D-E665CBFA62B7Q34467228-5834F2ED-1773-4F6C-AD2C-88D16B8465CFQ34555386-F876EB61-F606-4D8F-BC92-A58443E15B3AQ34591403-AFAD84E7-C0F7-4605-9ECC-5F5A374C4C9DQ34636735-1842D82A-1765-41EF-99F0-B466351F1E4BQ34754329-5DA7CA39-5507-49DE-B577-D2BE6244BA07Q34993145-D4C5554D-C2F9-496D-805F-8990DD0ACDA0Q35031403-38C478DE-FD3F-4C63-BCD7-B7773C7D9B36Q35038725-5851051A-904B-403A-AF20-E208630F9023Q35106844-9282EE45-5A87-4870-9A91-C334C4D62782Q35576181-625FF6F0-91FB-490A-B902-F10F334E390EQ35676486-3A13F8D2-481D-46E8-9D66-B88A868E55DDQ35739494-D39AD772-53AB-4496-B2D9-2A0C952477FDQ35740894-170F8545-D4D2-43CD-A306-D4917C1F141EQ35750567-4D056B36-9738-414C-AC0A-08A46E53277BQ36057887-9C962DAD-5574-446B-A559-E6E445DEF112Q36205970-BF78EB4C-5E2B-4B74-9EB9-FC28E5D16E88Q36276942-B0B1F47E-FDF3-447B-80BB-C360D941B23FQ36410157-0E637AF6-9CB2-405A-B7CD-7F8E001DF2DFQ36629288-F0B5A7E3-0C9C-42C1-A149-300B08E6FA5FQ36947802-5D82765C-941E-404B-A4D3-8B50335F8B96Q37213049-E0979C09-2AA3-47D9-80DA-A7505F563C8EQ37295112-64E424BF-DA41-4135-A98A-1579DA16740DQ37340403-86F946FF-F3BF-4C2E-9C04-7FCE0373D517Q37373040-9BB2D080-20FC-494E-AA8B-4257E6169A3DQ37379680-DCB2A673-49B5-4919-A6A1-06D11EA924A9Q37429734-34ACA554-2B4E-4C0D-BE31-FBEDA9033839Q37495206-3B61C4BD-6834-4162-A21C-1B7E2086CF74Q37577934-400B5E6A-9103-4569-8501-D679B52130DFQ37580329-D1F3847E-4B0C-4BE2-9EFF-00CDD943E1C0Q37623535-22010258-9189-4AEA-9A07-BE2DF8C0765BQ37670417-7CE4A7DB-99FA-4EF4-AD35-F9DFAA9C22DBQ37829880-8A187FD4-BB0D-4D47-9DEF-79C69A387E07Q37842585-0D5B9D8A-6786-49F2-A70B-25D70DC8B7CAQ37894667-B6EA4E40-7BDA-4205-BE73-7AB57CDA8F2D
P2860
Antitumor activity of sorafenib in FLT3-driven leukemic cells.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Antitumor activity of sorafenib in FLT3-driven leukemic cells.
@ast
Antitumor activity of sorafenib in FLT3-driven leukemic cells.
@en
Antitumor activity of sorafenib in FLT3-driven leukemic cells.
@nl
type
label
Antitumor activity of sorafenib in FLT3-driven leukemic cells.
@ast
Antitumor activity of sorafenib in FLT3-driven leukemic cells.
@en
Antitumor activity of sorafenib in FLT3-driven leukemic cells.
@nl
prefLabel
Antitumor activity of sorafenib in FLT3-driven leukemic cells.
@ast
Antitumor activity of sorafenib in FLT3-driven leukemic cells.
@en
Antitumor activity of sorafenib in FLT3-driven leukemic cells.
@nl
P2093
P356
P1433
P1476
Antitumor activity of sorafenib in FLT3-driven leukemic cells.
@en
P2093
P2888
P304
P356
10.1038/SJ.LEU.2404508
P577
2007-01-04T00:00:00Z
P5875
P6179
1052091031